Agenus

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Agenus
Sep 10, 2024, 13:38 | Insight
Agenus‘s latest data from the clinical trial of BOT/BAL in refractory sarcomas at ESMO24
Agenus shared on LinkedIn: “The Agenus team is headed to Barcelona for ESMO24. This Friday,…
Sep 5, 2024, 19:44 | Blog
A stage 4 young-onset cancer survivor speaks about the increase in colon cancer in young adults - Agenus
Agenus shared a post on LinkedIn: "Did you know, colorectal cancer has become the leading…
Sep 4, 2024, 11:47 | Dialogues
Dr. Benjamin Schlechter on Botensilimab: Practice-changing Drug | Most Promising Cancer Drugs 2024
In this episode of OncoDaily Interviews, Dr. Benjamin Schlechter, a distinguished medical oncologist at the…
Aug 29, 2024, 15:56 | Blog
Schedule a meeting with Agenus at ESMO24
Agenus shared on LinkedIn: "Attending ESMO24 in Barcelona from September 13-17? Our Medical Affairs team…
Aug 25, 2024, 20:10 | Blog
Urgent need for new therapies for colorectal cancer patients with MSS disease - Agenus
Agenus posted on LinkedIn: "Andrew Wortmann, Creative Director at Fight Colorectal Cancer, emphasizes the urgent…
Aug 10, 2024, 13:39 | Insight
Botensilimab’s effectiveness against tumours poorly responsive to conventional immunotherapy
Justin Stebbing shared a post on LinkedIn:  “Congratulations to Dhan Chand and the Agenus team…
Aug 10, 2024, 11:58 | Insight
Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy
In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…
Aug 9, 2024, 07:16 | Blog
Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers
Botensilimab is an investigational human Fc-enhanced CTLA-4 blocking antibody designed to boost both innate and…
Aug 7, 2024, 09:20 | Blog
Shushan Hovsepyan: Honored to interview Nils Eckardt
Shushan Hovsepyan shared a post by OncoDaily on LinkedIn, adding: ''I had the honor of…
Aug 2, 2024, 10:05 | Insight
Marianne Pearson about the urgent need for innovative treatment options for Colorectal cancer patients - Agenus
Agenus shared on LinkedIn: "Colorectal cancer is the second leading cause of cancer death in…
Aug 2, 2024, 08:47 | Dialogues
Driving Change in Oncology: the Vision of the Chief Medical Affairs Officer of Agenus
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Jul 31, 2024, 03:54 | Blog
What is Immunotherapy? - Agenus
Agenus posted on LinkedIn: "Curious about immunotherapy? Swipe to learn how this innovative treatment boosts…
Jul 29, 2024, 06:38 | Blog
Heart of a Warrior: Jennifer’s Triumphant Fight Against Cancer
Jennifer's story is a testament to strength and resilience. Faced with limited treatment options, she…
Jul 24, 2024, 08:09 | Blog
Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination
Gevorg Tamamyan shared on LinkedIn: "As I mentioned in my earlier post, we are ready in…
Jul 19, 2024, 02:00 | Blog
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…
Jul 18, 2024, 15:20 | Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jul 13, 2024, 14:25 | OncoDaily Pulse
OncoDaily Magazine - Inaugural Issue
We are excited to announce that the Inaugural issue of OncoDaily Magazine was launched on…
Jul 13, 2024, 14:15 | Dialogues
I never knew how close to this disease I would eventually become - Benny Johnson’s personal story with cancer
The new issue of OncoDaily Magazine had the privilege to feature an exclusive interview with Dr.…
Jul 13, 2024, 09:41 | Insight
IMMONC - Immune Oncology Research Institute's Experience in Advancing Clinical Cancer Research in Armenia
Cancer affects people across the world regardless of their socioeconomic status. However, low- and middle-income…
Jul 12, 2024, 10:06 | Career
14 individuals recognized for their exceptional contributions in shaping the future of pharmaceutical communications
Fierce Life Sciences Events shared on LinkedIn: "Day 2 of the Pharma PR and Communications…
Jul 11, 2024, 18:15 | Positive
Alexa Buffa named one of 2024's Industry Rising Stars by Fierce Life Sciences Events
Agenus shared on LinkedIn: "Congratulations to our own Alexa Buffa on being named one of…
Jul 11, 2024, 13:16 | Blog
Steven O'Day about how immunotherapy stands apart from traditional chemotherapy - Agenus
Agenus shared a post on LinkedIn:  . "Did you know immunotherapy activates the body’s own…
Jul 8, 2024, 12:29 | Drugs
Jennifer Buell: NCI Announces Availability of Botensilimab for Clinical Development
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, shared on X: “NCI Announces…
Jul 2, 2024, 09:22 | Societies
Inspired by engaging with the GI community at ESMOGI24 - Agenus
Agenus shared on LinkedIn: "That's a wrap on ESMOGI24! Our team was inspired by engaging…
Jul 2, 2024, 07:19 | Societies
25 Posts You Should Not Miss From ESMOGI24!
ESMOGI24 took place as an onsite event in Munich, Germany, from 26 to 29 June…
Jul 1, 2024, 16:15 | Blog
We need to hurry up, because cancer and patients cannot wait!
Gevorg Tamamyan, the Editor-in-chief of OncoDaily and CEO of Immune Oncology Research Institute, shared on…
Jul 1, 2024, 09:12 | Blog
Agenus - CTEP has announced the availability of botensilimab for clinical studies
Agenus shared on LinkedIn: “The National Cancer Institute (NCI)'s Cancer Therapy Evaluation Program (CTEP) has…
Jul 1, 2024, 02:25 | Blog
Insights from ESMOGI24 by Cathy Eng
ESMO GI 2024 took place from June 26 to 29 in Munich, Germany, featuring both…
Jun 28, 2024, 15:58 | Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:48 | Insight
Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24
Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…
Jun 28, 2024, 13:41 | Insight
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Agenus shared on their X page: "New data from the NEST clinical trial was presented…
Jun 28, 2024, 13:15 | Insight
The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO
ESMO (European Society for Medical Oncology) shared on LinkedIn: "Data from two presentations at ESMOGI24…
Jun 28, 2024, 13:09 | Insight
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…
Jun 28, 2024, 13:00 | Insight
Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer
Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…
Jun 28, 2024, 11:27 | Societies
12 Posts You Should Not Miss From Day 2 of ESMOGI24!
ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…
Jun 27, 2024, 12:44 | Societies
Discuss the future of immuno-oncology with Agenus at ESMOGI24
Agenus shared on LinkedIn: "If you are a physician attending ESMOGI24 in Munich from June…
Jun 25, 2024, 15:51 | Career
Agenus Regulatory is hiring Director of Regulatory Affairs
Eric J. Olson, Global Head of Regulatory at Agenus, shared on LinkedIn: "Agenus Regulatory is…
Jun 20, 2024, 15:04 | Societies
Agenus supports Fight Colorectal Cancer's webinar on navigating clinical trials
Quoting Agenus on LinkedIn: "We are proud to support Fight Colorectal Cancer’s latest webinar. Tune…
Jun 18, 2024, 23:25 | Insight
The future of immuno-oncology discussion with Agenus at ESMO GI 2024
Agenus shared a post on LinkedIn: “Are you a physician attending ESMO GI 24? Join…
Jun 15, 2024, 02:09 | Insight
Anthony El-Khoueiry: Botensilimab with expansion in MSS CRC; activity noted across multiple cold tumors
Anthony El-Khoueiry, Associate Professor of Medicine at University of Southern California Norris Comprehensive Cancer Center,…
Jun 13, 2024, 23:58 | Insight
Steven O'Day shared the latest data and insights from our botensilimab programs - Agenus
Agenus shared on LinkedIn: "Yesterday, our Chief Medical Officer, Dr. Steven O'Day, joined clinical experts…
Jun 13, 2024, 17:33 | Insight
Agenus' Phase 1 clinical trial results have been published in Nature
Agenus shared their publication on investigational immunotherapeutic agents in Nature: "Results from our Phase 1…
Jun 12, 2024, 03:29 | Blog
Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare Conference
Agenus shared on LinkedIn: “Tomorrow, Agenus is participating in the Goldman Sachs 45th Annual Global Healthcare…
Jun 10, 2024, 16:17 | Blog
Steven O’Day will be presenting an update on botensilimab programs at Nature Conferences’s event - Agenus
Quoting Agenus on X: "Tomorrow, Dr. Steven O’Day will be speaking at Nature Conferences’ Cancer Immunotherapy…
Jun 9, 2024, 08:12 | Blog
Gevorg Tamamyan: The Yvonne Award received a warm welcome from the international professional community
Gevorg Tamamyan shared on LinkedIn: "Last Friday, on May 31, the OncoDaily Party and Yvonne Awards Ceremony…
Jun 7, 2024, 11:02 | Career
Robin Taylor: Wonderful to have Eric Olson bringing his extensive Regulatory experience to Agenus
Robin Taylor, Chief Commercial Officer at Agenus, recently shared a post by Eric Olson, former…
Jun 4, 2024, 10:34 | Blog
Congratulations to Dr. Pashtoon Kasi on receiving the Yvonne Award from OncoDaily - Agenus
Agenus shared on LinkedIn: "Congratulations to Dr. Pashtoon Kasi on receiving the Yvonne Award from OncoDaily…
Jun 4, 2024, 05:09 | Insight
Join us in Chicago to discuss the future of immuno-oncology - Agenus
Agenus shared a post on LinkedIn:  “Are you a physician attending ASCO24? Join us in…
May 31, 2024, 23:43 | Blog
Dr. Benny Johnson shares his insights on the importance of innovative immunotherapy treatments - Agenus
Agenus shared a post on LinkedIn: "As Cancer Research Month nears a close, Dr. Benny Johnson shares…
May 30, 2024, 11:22 | Societies
A new analysis of bot/bal in metastatic MSS colorectal cancer at ASCO24 - Agenus
Agenus recently shared a post on LinkedIn: "Agenus is headed to ASCO24 where Dr. Marwan…
May 23, 2024, 09:37 | Blog
Agenus: We’re proud to share Dr. Joseph Grossman’s perspective of our investigational immunotherapy pipeline
Agenus shared a post on LinkedIn: "At Agenus, we aim to transform care for individuals living…
May 17, 2024, 11:18 | Drugs
Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA
Agenus shared on LinkedIn: “Today we announced that Agenus has been granted a Type B…
May 13, 2024, 07:25 | Blog
Partnership between Ligand Pharmaceuticals and Agenus
Ligand Pharmaceuticals shared on their LinkedIn page: "We are excited to announce our latest royalty…
May 12, 2024, 03:08 | Blog
CEO of Agenus, Garo Armen shares details on our royalty financing agreement with Ligand Pharmaceuticals
Agenus shared on LinkedIn: “‘With this infusion of capital, we are poised to accelerate the…
May 9, 2024, 12:46 | Blog
Zack Armen: A major transaction with Ligand Pharmaceuticals and Agenus
Zack Armen, Head of Investor Relations at Agenus, shared a post on LinkedIn: ''Yesterday we…
Apr 13, 2024, 15:16 | Blog
Zack Armen: This is incredibly exciting for patients with neoadjuvant colon and rectal cancer
Zack Armen, Head of Investor Relations at Agenus, shared a post by Pashtoon Kasi, Oncologist…
Apr 13, 2024, 06:43 | Opinion
Agenus announced updated Phase 1 data and progress botensilimab/balstilimab combination in metastatic MSS colorectal cancer
Agenus shared on LinkedIn: "Today we announced updated Phase 1 data and progress on our investigational…
Apr 9, 2024, 15:56 | Blog
We’ve been energized and inspired by our time at AACR2024 - Agenus
Agenus shared a post on LinkedIn: “We’ve been energized and inspired by our time at AACR2024.…
Apr 9, 2024, 09:15 | Blog
Nicholas Skiadas: Today I get my first dose of Botensilimab/Balstilimab
Nicholas Skiadas, Cardiologist in Jacksonville, Florida, shared a post on X: "Hopefully we are headed…
Mar 31, 2024, 23:33 | Blog
Steven O'Day: Please take one lesson with you as Colorectal Cancer Awareness Month nears it ends - get screened!
Steven O'Day shared a post on LinkedIn: "Please take one lesson with you as Colorectal Cancer…
Mar 30, 2024, 14:29 | Career
Melissa Orilall Gets Promoted to Executive Director of Global Financial Operations at Agenus
Melissa Orilall shared on LinkedIn: "I’m happy to share that I’m starting a new position…
Mar 30, 2024, 14:12 | Blog
Jennifer Buell: I ride in the Pan Mass Challenge to eliminate the premature loss of so many important lives, to stand with our fighters, to illuminate hope
Jennifer Buell, the President and Chief Executive Officer of MiNK Therapeutics, shared on LinkedIn: "I…
Mar 28, 2024, 15:32 | Career
Claire Nolan Takes on Managerial Role at Agenus responsible for the Global Events and Special Projects
Claire Nolan, shared on LinkedIn: "I’m happy to share that I’m starting a new position…
Mar 10, 2024, 16:44 | Blog
Steven O’Day: March is Colorectal Cancer Awareness Month—a time where I am reminded of the resilience and courage of those affected by this disease
Steven O’Day shared on LinkedIn: "March is Colorectal Cancer Awareness Month—a time where I am…
Mar 5, 2024, 20:08 | Blog
Agenus joins the colorectal cancer community around the globe to bring attention and raise awareness on the second leading cause of cancer death in the United States - Agenus
Mar 3, 2024, 05:48 | Blog
Check out the latest 'Ask the Expert' webinar hosted by Melanoma Research Foundation - Agenus
Agenus shared a post on LinkedIn: ''In case you missed it, check out the latest…
Feb 22, 2024, 17:59 | Blog
“The Immuno-Oncology Curve” with Dr. Steven O'Day – Guests are Dr. Joseph Grossman and Dr. Benny Johnson
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "In the latest episode…
Feb 14, 2024, 14:59 | Blog
Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL
Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…
Feb 14, 2024, 13:40 | Insight
Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer
Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn: "Happy to share…
Jan 27, 2024, 15:39 | Blog
Agenus joined oncology leaders from across the globe at ASCO GI (GI24)
Agenus recently posted on their LinkedIn page: "Agenus joined oncology leaders from across the globe…
Dec 13, 2023, 17:13 | Blog
Angela V. Hafner: Agenus to Receive $25 Million from Bristol Myers Squibb
Angela V. Hafner, Associate Director, External Innovation at Agenus, made the following post on LinkedIn:…
Nov 20, 2023, 10:30 | Insight
Steven O'Day: I am thrilled to announce the upcoming launch of “The Immuno-Oncology Curve”
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "I am thrilled to…
Nov 19, 2023, 00:23 | Blog
Steven O'Day: We are looking for an experienced pharma medical director (MD) with experience in oncology and immunotherapy and BLA submissions to join our passionate team and exciting pipeline
Nov 17, 2023, 13:59 | Insight
Revolutionizing Cancer Immunotherapy: Next-Gen CTLA-4 Targeting and Combination Therapies
Dive into the groundbreaking research published in "Oncology Immunology" (2023), where leading scientists Nils-Petter Rudqvist,…
Nov 3, 2023, 12:10 | Drugs
Steven O'Day shared their recent webinar presented by Endpoints News on “The Next I-O Revolution”
Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn: ''Did you catch our…
Oct 30, 2023, 19:47 | Opinion
Jeniece Waite: Agenus is hiring clinical scientists
Jeniece Waite, Senior Recruiting Manager at Agenus, shared a post on LinkedIn: "As a Clinical…
Oct 29, 2023, 03:34 | Drugs
Steven O'Day: The research we shared underscores BOT’s broad potential utility across multiple advanced solid tumors
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "It was an exciting…
Oct 24, 2023, 14:05 | Drugs
Agenus is proud to unveil the latest research from our investigational botensilimab programs - Agenus
Agenus shared a post on LinkedIn: "Agenus is proud to unveil the latest research from…
Oct 23, 2023, 15:23 | Drugs
Pashtoon Kasi: So excited to move the field forward with novel therapies for patients with pMMR/MSS Colorectal Cancer
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared on his Twitter:…
Oct 23, 2023, 13:31 | Drugs
At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma
Agenus shared on their LinkedIn page: "At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational…
Oct 19, 2023, 17:28 | Blog
Manush Avagyan: I'm now diving into a year of skill refinement as a physician, scientist, and leader at Harvard Medical School (HMS)
Manush Avagyan, Associate Medical Director at Agenus, recently posted on her LinkedIn: "Exciting News: Harvard…
Oct 15, 2023, 19:05 | Blog
Steven O'Day: I am thrilled to be joining Dr. Benjamin Schlechter, Dr. Pashtoon Kasi, and Phuong Ly-Gallagher for an engaging discussion on “The Next I-O Revolution”.
Oct 15, 2023, 14:10 | Blog
Jennifer Buell: SaponiQx, an Agenus Inc. company revolutionizes access with sustainable, scalable supply of the vital QS-21 STIMULON
Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared on X/Twitter: "SaponiQx, an Agenus…
Oct 11, 2023, 22:39 | Opinion
Agenus completed the planned patient enrollment of its Phase 2 clinical trial evaluating investigational agents botensilimab (BOT) and balstilimab (BAL) in advanced colorectal cancer. - Agenus
Sep 25, 2023, 16:07 | Insight
Steven O'Day: Today is World Cancer Research Day, which is a good day for me to share three things.
Quoting Steven O'Day, the Chief Medical Officer at Agenus, on LinkedIn: "Today is World Cancer…
Sep 21, 2023, 17:50 | Insight
TIGIT bispecific program is advancing in clinical trials for non-small cell lung and gastric cancers. - Agenus
Agenus shared on LinkedIn: “Our partner, Bristol Myers Squibb, unveiled exciting updates at their recent…
Sep 21, 2023, 11:16 | Drugs
Pashtoon Kasi: Are we on the verge of a new drug combo for colorectal cancer?
Pashtoon Kasi, the Director of Colon Cancer Research at Weill Cornell Medicine, shared on X/Twitter:…
Aug 22, 2023, 18:09 | Career
Beatrice Duvert: I’m happy to share that I’m starting a new position as an Associate Program Manager at Agenus!
Quoting Beatrice Duvert, Associate Program Manager at Agenus, on LinkedIn: "I’m happy to share that…
Aug 14, 2023, 18:19 | Insight
Tune in to "Innovation Unleashed: Exploring the Intersection of Science and Creativity - An Unconventional Growth Strategy" - Agenus
Quoting from Agenus LinkedIn: ''Thank you, Sabine Hutchison, for hosting us on an insightful episode of…
Jul 29, 2023, 17:45 | Blog
Agenus is thrilled to welcome the newest members of executive leadership team
Agenus is thrilled to welcome the newest members of our executive leadership team: Robin Taylor,…
Jul 1, 2023, 06:00 | Drugs
Agenus’ botensilimab/balstilimab combination achieves unprecedented survival in advanced colorectal cancer
In a post by Agenus on Linkedin, it says, "ESMO Late-Breaking GI Data: Agenus’ botensilimab/balstilimab…
Jun 13, 2023, 17:24 | Insight
In 16 months, we have registered more cancer clinical trials in Armenia, than throughout all the years before that - Gevorg Tamamyan
Last year, on February 4th I was doing a presentation about the cancer clinical trials…
May 24, 2023, 15:51 | Positive
A Relentless Pursuit on Behalf of Patients: The Work of Cancer Research
Every May, the American Association for Cancer Research marks National Cancer Research Month #NCRM, committed to raising awareness…
May 14, 2023, 06:04 | Career
Beth Wensley is appointed as Associate Director of Protein Sciences at Agenus
"Introducing Beth Wensley, our Associate Director of Protein Sciences. As one of Agenus' original employees…
All: 94 Posts: 1 - 100
Special Coverage